Astellas suffers pancreatic cancer failure with Vyloy

[ad_1] A year ago, Astellas was celebrating the first-in-class approval of its claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into pancreatic cancer has hit the buffers. The 393-patient phase 2 GLEAM study compared the combination of Vyloy (zolbetuximab) with chemotherapy (gemcitabine and nab-paclitaxel) to chemotherapy alone, but…

Read More